Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Oncology

Background:

• Signal transducer and activator of transcription 3 (STAT3) is a key regulator of cell growth and survival.
• Constitutively active STAT3 signaling is implicated in various cancers, making it a promising therapeutic target.
• Targeting the STAT3 SH2 domain offers a specific approach to inhibit its function.

Purpose of the Study:

• To design and synthesize novel, conformationally constrained small-molecule inhibitors targeting the STAT3 SH2 domain.
• To evaluate the potency, cell permeability, and biological activity of these inhibitors.
• To assess the efficacy of a lead compound in inhibiting STAT3 signaling and cancer cell proliferation.

Main Methods:

• Structure-based drug design was employed to create inhibitors.
• In vitro biochemical assays were used to determine binding affinity (K(i)).
• Cell-based assays assessed STAT3 signaling inhibition, cell growth, and apoptosis induction in cancer cell lines.

Main Results:

• A class of potent, cell-permeable small-molecule inhibitors targeting the STAT3 SH2 domain was successfully designed.
• Compound 11 (CJ-1383) demonstrated strong binding to STAT3 with a K(i) of 0.95 µM.
• Compound 11 dose-dependently inhibited STAT3 signaling, suppressed cancer cell growth, and induced apoptosis in MDA-MB-468 cells.

Conclusions:

• Conformationally constrained small molecules can effectively inhibit the STAT3 SH2 domain.
• Compound 11 (CJ-1383) represents a promising lead compound for developing STAT3-targeted cancer therapies.
• Targeting constitutively active STAT3 signaling is a viable strategy for cancer treatment.